Vixiane Sengsouvanh, DDS | |
7277 Lone Pine Dr., Ste. C 105, Rancho Murieta, CA 95683 | |
(916) 354-2637 | |
(916) 354-3270 |
Full Name | Vixiane Sengsouvanh |
---|---|
Gender | Male |
Speciality | Dentist |
Location | 7277 Lone Pine Dr., Rancho Murieta, California |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1568664498 | NPI | - | NPPES |
48994 | Other | CA | STATE LICENSE NUMBER |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
122300000X | Dentist | 48994 (California) | Primary |
Mailing Address | Practice Location Address |
---|---|
Vixiane Sengsouvanh, DDS Po Box 1451, Rancho Murieta, CA 95683-1451 Ph: (916) 354-2637 | Vixiane Sengsouvanh, DDS 7277 Lone Pine Dr., Ste. C 105, Rancho Murieta, CA 95683 Ph: (916) 354-2637 |
News Archive
A type of cell plentiful in the brain, long considered mainly the stuff that holds the brain together and oft-overlooked by scientists more interested in flashier cells known as neurons, wields more power in the brain than has been realized, according to new research published today in Science Signaling.
By developing a new technology to analyze proteins in single human cells, York University professor Sergey Krylov hopes to create a diagnostic ‘Swiss Army Knife' that can eventually help to diagnose and treat a variety of currently incurable diseases like cancer, diabetes, Parkinson's and Alzheimer's.
A new study spearheaded by the University of Pittsburgh School of Medicine has determined that environmental monitoring of institutional water systems can help to predict the risk of hospital-acquired Legionella pneumonia, better known as Legionnaires disease.
Zenobia Therapeutics, Inc. the leader in fragment-based lead discovery for CNS diseases, announced today a research collaboration with H. Lundbeck A/S utilizing Zenobia's expertise in protein expression and x-ray crystallography for the Parkinson's disease target, LRRK2. Under the agreement, Zenobia will continue to use its capabilities in fragment-based lead discovery (FBLD) to advance its internal LRRK2 drug discovery program independently of Lundbeck.
› Verified 7 days ago